Opinion
Video
Novel Treatment Options for Bronchiectasis
Panelists discuss how emerging DPP1 inhibitor therapies target neutrophil serine proteases to reduce neutrophilic inflammation and neutrophil extracellular trap formation in bronchiectasis.
Clinical Brief: Emerging Therapies for Bronchiectasis
Main Discussion Topics
- DPP1 inhibitors target neutrophil inflammation in bronchiectasis.
- Eosinophilic bronchiectasis (approximately 30% of cases) benefits from targeted therapies.
- Approaches to treatment vary based on inflammatory phenotype.
Key Points for Physicians
- DPP1 inhibitors:
- Target abnormal neutrophil function and reduce neutrophil serine proteases
- May prevent formation of neutrophil extracellular traps
- Aim to reduce exacerbations and disease progression
- For eosinophilic bronchiectasis (30% of cases):
- Inhaled corticosteroids are beneficial
- Anti-IL5 therapies show promise
- Biologic therapies are being investigated
- Discourage inhaled corticosteroids in neutrophilic bronchiectasis (70% of cases) due to potential infection risk.
Notable Insights
Peripheral eosinophil counts may help guide treatment decisions similar to their use in chronic obstructive pulmonary disease management, with different thresholds being investigated.
Clinical Significance
Emerging therapies targeting specific inflammatory pathways show promise for more precise treatment of bronchiectasis based on inflammatory phenotype.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
